In spring of 2023, the Biden administration, with bipartisan support from Congress, approved over-the-counter (OTC) sale of naloxone, the drug that reverses life-threatening opioid overdoses. Sales to Americans followed in the summer and fall of 2023, strengthening the use of this important tool in the battle against overdose deaths, which exceed 100,000 per year. In the year that has followed, the Biden administration has pursued additional steps to advance access, market affordability, and use of naloxone.
Moderator J. Stephen Morrison, Senior Vice President and Director, CSIS Global Health Policy Center, will join Dr. Rahul Gupta, Director, White House Office of National Drug Control Policy, and Paul Williams, Senior Vice President, Emergent BioSolutions, and Heather Saunders, Senior Research Manager, KFF, for a conversation on the lessons and gains of the past year, and a future agenda to ensure this tool has optimal impact.
This event is made possible through general support to the Center for Strategic and International Studies.
